Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Meiragtx Holdings Plc (MGTX)

Meiragtx Holdings Plc (MGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 320,892
  • Shares Outstanding, K 64,307
  • Annual Sales, $ 14,020 K
  • Annual Income, $ -84,030 K
  • 60-Month Beta 1.31
  • Price/Sales 22.39
  • Price/Cash Flow N/A
  • Price/Book 2.26
Trade MGTX with:

Options Overview Details

View History
  • Implied Volatility 116.65% ( -281.47%)
  • Historical Volatility 34.58%
  • IV Percentile 83%
  • IV Rank 26.96%
  • IV High 398.13% on 04/25/24
  • IV Low 12.77% on 08/10/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 50
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 2.29
  • Today's Open Interest 585
  • Open Int (30-Day) 1,269

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +48.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.68 +6.62%
on 04/26/24
5.90 -15.42%
on 04/09/24
-0.54 (-9.76%)
since 04/02/24
3-Month
4.68 +6.62%
on 04/26/24
6.85 -27.15%
on 03/18/24
-0.92 (-15.57%)
since 02/02/24
52-Week
3.49 +42.98%
on 10/25/23
8.35 -40.24%
on 06/09/23
-0.20 (-3.85%)
since 05/02/23

Most Recent Stories

More News
Icosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue Estimates

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ICVX : 15.31 (-0.91%)
MGTX : 4.99 (unch)
Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Lags Revenue Estimates

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -1.61% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

XENE : 43.00 (+1.20%)
MGTX : 4.99 (unch)
Certara, Inc. (CERT) Matches Q1 Earnings Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 1.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CERT : 17.61 (+1.79%)
MGTX : 4.99 (unch)
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -66% and 66.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

MGTX : 4.99 (unch)
INVO : 0.9310 (-6.90%)
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

-- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)...

MGTX : 4.99 (unch)
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EPZM : 1.4700 (-1.34%)
MGTX : 4.99 (unch)
Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -54.55% and 3.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VNDA : 4.68 (-1.89%)
MGTX : 4.99 (unch)
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

- Credit facility is collateralized by MeiraGTx’s wholly-owned manufacturing facilities in London, UK and Shannon, Ireland - $75 million at closing...

MGTX : 4.99 (unch)
MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

• The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated ...

MGTX : 4.99 (unch)
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -42.86% and 39.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MGTX : 4.99 (unch)
ANGN : 10.0000 (+2.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR,...

See More

Key Turning Points

3rd Resistance Point 5.19
2nd Resistance Point 5.12
1st Resistance Point 5.06
Last Price 4.99
1st Support Level 4.93
2nd Support Level 4.86
3rd Support Level 4.80

See More

52-Week High 8.35
Fibonacci 61.8% 6.49
Fibonacci 50% 5.92
Fibonacci 38.2% 5.35
Last Price 4.99
52-Week Low 3.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar